Spinal muscular atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and wasting due to degeneration of alpha motor neurons in the anterior horns of the spinal cord. This results in a loss of innervation of the muscles, causing them to become wasted and weak. SMA can manifest itself in various forms, such as an acute illness that manifests itself in infancy, or later forms that begin in childhood or adulthood. The disease belongs to a group of inherited pathologies and is caused by a mutation in the SMN1 gene, which leads to a deficiency of the SMN protein, which is essential for the functioning of motor neurons.
History of the disease and interesting historical facts
The history of spinal muscular atrophy dates back to the 19th century, when the first descriptions of the disease began to appear in medical literature. In 1891, physician G. D. Martin published his observations on muscular atrophy and its connection with spinal cord diseases. It is noteworthy that at the beginning of the 20th century, the hereditary nature of SMA was determined. In 1995, a mutation in the SMN1 gene was isolated, which was a significant step in understanding the pathogenesis of the disease. The development and implementation of genetic tests in the 2000s opened up new horizons for the diagnosis and treatment of SMA, allowing for the detection of the disease at early stages and the development of personalized approaches to therapy.
Epidemiology
According to epidemiological studies, the incidence of spinal muscular atrophy in newborns is approximately 1 in 10,000 live births. Depending on geographic and ethnic factors, this figure may vary, but in general, SMA occurs with similar frequency throughout the world. Given that this disease has an autosomal recessive type of inheritance, the risk of its occurrence is significantly increased in families with already registered cases of SMA. About 1 in 40 people carries a mutation of the SMN1 gene, which makes the disease relatively common in certain population groups.
Genetic predisposition to this disease
Spinal muscular atrophy is caused by mutations in the SMN1 gene, located on chromosome 5. To date, more than 90% cases of SMA have been linked to deletions or mutations in this gene. In addition, there is the SMN2 gene, which is considered a “modifying gene” because it also codes for the SMN protein but does not provide full functionality. The number of copies of this gene can affect the severity of the disease: the more copies of SMN2, the more favorable the prognosis for the patient. Mutations in other genes, such as UFM1 or ZPR1, although less common, can also contribute to the development of rare forms of SMA.
Risk factors for the development of this disease
The most significant risk factors associated with spinal muscular atrophy include:
- Hereditary predisposition - the presence of cases of SMA in the family.
- The presence of mutations in the SMN1 and SMN2 genes.
- Genetic markers in populations (eg, among people of European descent, the risk is higher).
Apart from genetic aspects, environmental factors generally do not play a significant role in the development of SMA. However, physical and chemical factors such as toxic substances and infections may be the subject of research, but preclinical data are not yet available.
Diagnosis of this disease
Diagnosis of spinal muscular atrophy begins with an assessment of clinical symptoms, which may include:
- Muscle weakness and atrophy, especially proximal.
- Decreased muscle tone.
- Breathing problems.
- Delay in motor skills in children.
Laboratory tests include genetic testing for mutations in the SMN1 gene. Imaging tests, such as MRI, may also be performed to help rule out other neurological conditions. The differential diagnosis includes diseases such as amyotrophic lateral sclerosis (ALS), myasthenia gravis, and other inherited myopathies.
Treatment
Treatment of spinal muscular atrophy is aimed at slowing the progression of the disease and improving the quality of life of patients. Today, there are several approaches to therapy, including:
- Pharmacological treatments such as nusinersen (Spinraza), which modify the expression of the SMN2 gene.
- Gene therapy strategies such as onasemnogene abeparvovec (Zolgensma) target the SMN protein deficiency.
- Physical therapy and rehabilitation treatments to maintain muscle strength and flexibility.
- Surgical interventions to correct scoliosis or other orthopedic problems.
Further research and clinical trials are ongoing to find new treatments.
List of medications used to treat this disease
Among the drugs used for the treatment of spinal muscular atrophy, the following can be distinguished:
- Nusinersen (Spinraza)
- Onasemnogene abeparvovec (Zolgensma)
- Risdiplam (Evrysdi)
These drugs aim to improve SMN protein levels and offer patients a chance to improve their condition and slow the progression of the disease.
Disease monitoring
Monitoring of patients with spinal muscular atrophy includes regular examinations to assess overall fitness, respiratory function, and symptom progression. Prognosis depends on the type of SMA, age of onset, and availability of effective therapy. Complications may include respiratory infections, nutritional problems, and musculoskeletal problems.
Age-related features of the disease
Spinal muscular atrophy can occur in different age groups:
- SMA type 1 (Dwarfism) - manifests itself in the first months of life, high risk of severe complications.
- SMA type 2 - from 6-18 months; need for supportive methods may be noted.
- SMA types 3 and 4 - appear in childhood or adulthood and usually have a more favorable prognosis.
Each form has its own clinical characteristics and treatment approaches.
Questions and Answers
- What are the main symptoms of spinal muscular atrophy? The main symptoms include muscle weakness, muscle atrophy, difficulty breathing, and delays in motor skills.
- Can spinal muscular atrophy be cured? There is currently no complete cure, but there are effective treatments that can significantly improve the patient's condition and slow the progression of the disease.
- How is the risk of developing spinal muscular atrophy determined? The risk is significantly increased if there is a history of the disease in the family, as SMA is transmitted in an autosomal recessive manner.
- What diagnostic methods are used to detect SMA? Diagnosis involves clinical examination, genetic testing and, if necessary, imaging techniques such as MRI.
- What is the prognosis for patients with spinal muscular atrophy? The prognosis depends on the type of SMA, the treatment regimen, and the timeliness of diagnosis; many patients can have a normal life expectancy with adequate treatment.
